Loading…
Based on limited metadata, the FDA issued a Warning Letter to Brassica Pharma Pvt. Ltd. on July 11, 2024, regarding drug products. While the specific violations cannot be detailed without access to the full letter text, the warning indicates the company failed to meet FDA regulatory requirements for pharmaceutical manufacturing or operations. This action falls under the FDA's drug product oversight authority, though the specific issuing office and violation count are not specified in the available metadata.